Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-01488 in B-Cell Malignancies
NCT05275504Phase 1Unknown
- Sponsor
- TransThera Biosciences
- Start
- Jun 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TT-01488 in B cell malignancies (2 arms), sponsored by TransThera Biosciences. Primary endpoints: Dose-Limiting Toxicity up to 28 days, Dose Recommended for Dose Expansion and 1 more. Status: unknown.
02
Drugs
TT-01488
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT05275504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275504.